Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15115934 | 0.81 | DUT (0.31) | DUT | |
| SCHEMBL4714377 | 0.81 | BTN3A1 (0.33) | DUT | |
| SCHEMBL14059079 | 0.79 | DUT (0.30) | DUT | |
| SCHEMBL15817363 | 0.78 | — | — | |
| SCHEMBL4717834 | 0.78 | — | — | |
| SCHEMBL23532351 | 0.76 | — | — | |
| SCHEMBL23573656 | 0.75 | TET2 (0.37) | DUT | |
| SCHEMBL10592319 | 0.74 | DUT (0.32) | DUT | |
| SCHEMBL13518253 | 0.74 | DUT (0.35) | DUT | |
| SCHEMBL11580466 | 0.74 | DUT (0.42) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996571-B1 | TETRACYCLIC STEROID DERIVATIVES USEFUL AS PROGESTERONE RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-20 | — | — | EP | disclosed |
| EP-1996571-A2 | TETRACYCLIC STEROID DERIVATIVES USEFUL AS PROGESTERONE RECEPTOR MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2008-12-03 | — | — | EP | disclosed |
| US-7390831-B2 | contraception, secondary amenorrhea; dysfunctional bleeding; uterine leiomyomata; endometriosis; polycystic ovary syndrome; carcinomas, adenocarcinomas, Syndrome X, diabetes; 3'H-spiro-[[1,3]-dioxol-11,12-Dihydroxy-13-methyl-1,6,7,8,11,12,13,14,15,16-decahydro-2H-cyclopenta[a]phenanthrene-3,17-dione | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-24 | — | — | US | disclosed |
| WO-2007098384-A2 | TETRACYCLIC STEROID DERIVATIVES USEFUL AS PROGESTERONE RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-30 | — | — | WO | disclosed |
| US-20070197634-A1 | TETRACYCLIC STEROID DERIVATIVES USEFUL AS PROGESTERONE RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-23 | — | — | US | disclosed |
| EP-0987269-B1 | SALTS OF OPTICALLY ACTIVE SULFOXIDE DERIVATIVE | SANKYO CO (JP) | 2003-08-13 | — | — | EP | disclosed |
| US-6448247-B1 | TACHYKININ RECEPTOR ANTAGONIST; ESPECIALLY TO THE RECEPTORS FOR SUBSTANCE P (WHICH RECEPTORS ARE GENERALLY REFERRED TO AS ?NEUROKININ 1 RECEPTORS?) | SANKYO COMPANY, LIMITED (JP) | 2002-09-10 | — | — | US | disclosed |
| US-6362179-B1 | PSYCHOLOGICAL DISORDERS; NERVOUS SYSTEM DISORDERS | SANKYO COMPANY, LIMITED (JP) | 2002-03-26 | — | — | US | disclosed |
| US-6159967-A | Heterocyclic compounds having tachykinin receptor antagonist activity their preparation and their use | SANKYO COMPANY, LIMITED (JP) | 2000-12-12 | — | — | US | disclosed |
| EP-0987269-A1 | SALTS OF OPTICALLY ACTIVE SULFOXIDE DERIVATIVE | Sankyo Company Limited (JP) | 2000-03-22 | — | — | EP | disclosed |
| EP-0776893-A1 | Azaheterocyclic compounds having tachykinin receptor antagonist activity; Nk1 and NK2 | SANKYO COMPANY LIMITED (JP) | 1997-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197634-A1 | TETRACYCLIC STEROID DERIVATIVES USEFUL AS PROGESTERONE RECEPTOR MODULATORS | NR5A1, NR3C2, NR3C1 | DUT 4020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.